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Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only
overcome, but better yet, exploit intra-tumoural hypoxia. Despite being successful in vitro
and in vivo, HAPs are yet to achieve successful results in clinical settings. It has been
hypothesised that this lack of clinical success can, in part, be explained by the insufficiently
stringent clinical screening selection of determining which tumours are suitable for HAP
treatments. Taking a mathematical modelling approach, we investigate how tumour proper-
ties and HAP-radiation scheduling influence treatment outcomes in simulated tumours. The
following key results are demonstrated in silico: (i) HAP and ionising radiation (IR) mono-
therapies may attack tumours in dissimilar, and complementary, ways. (ii) HAP-IR schedul-
ing may impact treatment efficacy. (iii) HAPs may function as IR treatment intensifiers. (iv)
The spatio-temporal intra-tumoural oxygen landscape may impact HAP efficacy. Our in sil-
ico framework is based on an on-lattice, hybrid, multiscale cellular automaton spanning
three spatial dimensions. The mathematical model for tumour spheroid growth is parame-
terised by multicellular tumour spheroid (MCTS) data.
Author summary
When cancer patients present with solid tumours, the tumours often contain regions that
are oxygen-deprived or, in other words, hypoxic. Hypoxic tumour regions are more resis-
tant to conventional anti-cancer therapies, such as chemotherapy and radiotherapy, and
therefore tumour hypoxia may complicate treatments. Hypoxia-activated prodrugs con-
stitute a conceptually elegant approach to not only overcome, but better yet, exploit
tumour hypoxia. Hypoxia-activated prodrugs are drugs that act as Trojan horses, they are
theoretically harmless vehicles that are converted into warheads when they reach their
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targets: hypoxic tumour regions. Despite being conceptually clever and successful in
experimental settings, hypoxia-activated prodrugs are yet to achieve successful results in
clinical trials. It has been hypothesised that this lack of clinical success can, in part, be
explained by an insufficiently stringent clinical screening selection of determining which
tumours are suitable for hypoxia-activated prodrug treatments. In this article, we investi-
gate how simulated tumours with different oxygen landscapes respond to anti-cancer
treatments that include hypoxia-activated prodrugs, either alone or in combination with
radiotherapy. Our simulation framework is based on a mathematical model that describes
how individual cancer cells in a tumour divide and respond to treatments. We demon-
strate that the efficacy of hypoxia-activated prodrugs depends on both the treatment
scheduling and the oxygen landscapes of the simulated tumours.
Introduction
Oxygen concentrations vary across solid tumours and, although tumours present with high
diversity across patients [1], hypoxic regions are prevalent tumour features, commonly pro-
voked by inadequate oxygen supply and high tumour growth rates [2–11]. Hypoxia signifi-
cantly impacts tumour dynamics, treatment responses and, by extension, clinical outcomes [6,
9, 12]. Hypoxia may alter cellular expressions of genomes, proteins and epigenetic traits [2],
and such hypoxia-induced alterations may cause hypoxic cancer cells to become more resistant
to apoptosis [13]. Hypoxia may also alter the metabolism of cells [13], promote angiogenesis
by activating associated genes [14] and upregulate efflux systems [15]. Thus hypoxia may both
protect and progresses solid tumours [12, 13] and, accordingly, severe tumour hypoxia is asso-
ciated with tumours that are difficult to treat and, by extension, poor prognoses for patients [2,
7]. It is well established that hypoxic regions in solid tumours express reduced sensitivity to
radiotherapy and a plethora of chemotherapeutic drugs [2, 6–9, 11, 13, 14, 16–18]. Hypoxic
cancer cells in a solid tumour are naturally located far away from active oxygen sources, i.e.
blood vessels [7], and therefore drug molecules that are of large size or tightly bound to cell
components may not reach hypoxic tumour cells at all [14]. Moreover, genes associated with
chemo-resistance may be upregulated by hypoxia [19]. Hypoxia is also regarded to be one of
the main factors contributing to radiotherapy failure [14] and radiation-induced DNA dam-
age, especially in the form of double strand breaks, is more easily self-repaired by cells under
hypoxic conditions [20].
Due to their severe impact on conventional anti-cancer therapies, such as chemotherapy
and radiotherapy, hypoxic cancer cells, and their central mediators [2], have for the last
decades been considered to be important treatment-targets [1, 14]. In treatment scenarios in
which rapid tumour re-oxygenation does not occur, hypoxic tumour regions can, instead, be
more directly targeted. In fact, multiple ways to handle tumour hypoxia have been explored.
One approach to combating intra-tumoural hypoxia is to increase the tumour oxygenation as
part of a neoadjuvant treatment [19]. A second approach to overcome hypoxia is to selectively
target hypoxic cancer cells for treatment-sensitising or eradication [4]. A third and conceptu-
ally elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia is
realised by hypoxia-activated prodrugs (HAPs) [14]. HAPs are bioreductive prodrugs that
reduce, and thus convert, into cytotoxic agents upon reaching hypoxic (tumour) regions [13,
18]. Theoretically, they act as Trojan horses, ideally being essentially harmless until they are
converted into warheads in targets, i.e. hypoxic (tumour) regions. The tumour-targeting ability
of HAPs is based on the premise that oxygen concentrations in hypoxic tumour regions reach
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exceptionally low levels, and that such low oxygen levels are much more prevalent in tumours,
than in the body tissue that locally surrounds the tumours [13]. Indeed physoxia (the term
commonly used to describe oxygen levels found in several types of normal tissue), ranges
between 10 and 80 mmHg, and a cancer cell is commonly classified as hypoxic if it has a partial
pressure of oxygen (pO2) value of 10 mmHg or less [5]. Solid tumours commonly display
regions that are even more hypoxic, where pO2 values may drop below 5 mmHg [5]. Conse-
quently, HAPs theoretically constitute a means to effectively target hypoxic tumour regions
whilst keeping toxic effects localised to tumours, in great part sparing the remaining host sys-
tem from harmful toxicity and unwanted side effects.
HAPs transform into activated drugs (AHAPs) via reductive metabolism in sufficiently
hypoxic environments [3, 14], and the AHAPs can in turn achieve cytotoxic effects in cells
[21]. Freely available molecular oxygen may inhibit this bioreduction, and thus HAPs remain
(for the most part) more intact, and by extension less toxic, in well-oxygenated environments
[13]. Once activated, certain AHAPs may diffuse into their local surroundings. Thus, via
bystander effects, for certain HAP drugs, AHAPs may infer damage to cells in which the HAP-
to-AHAP bioreduction did not occur. However, a few recent studies dispute the impact of
these bystander effects on the overall treatment outcome [22]. In the mathematical model uti-
lised in this study, the dispersion of HAPs and AHAPs obey mechanistic diffusion equations,
and the reach of AHAPs can easily be modified by altering coefficients in the AHAP diffusion
equation. Thus the influence of bystander effects on the treatment outcome is allowed to range
from negligible to highly influential in our mathematical model.
Multiple HAPs have been evaluated for their clinical potential, both as monotherapies and
as part of combination therapies [2, 8]. Class I HAPs are activated in moderately hypoxic envi-
ronments whilst Class II HAPs require more severe hypoxia to undergo the HAP to AHAP
bioreduction [23]. One such Class II HAP is evofosfamide, or TH-302, which has been tested
in clinical Phase I-III trials [2, 19]. TH-302 bioreduces to its activated form, bromo-isopho-
sphoramide mustard (Br-IPM), in hypoxic tumour regions, and Br-IPM is a DNA-crosslink-
ing agent [22]. Multiple in vitro and in vivo studies have validated this prodrug’s preclincal
success and, by extension, its clinical potential [6, 7, 9, 10, 12, 17, 21, 24–28]. Multimodality
treatment strategies combining HAPs, particularly Class II HAPs, with ionising radiation (IR)
may be particularly promising [8, 9, 27–29] as the two therapies conceptually complement
each other: HAPs target hypoxic tumour regions whilst radiotherapy is most effective against
well-oxygenated tumour regions. Thus, in principal, HAP-IR combination treatments have
the ability to produce multifaceted attacks on tumours.
Despite HAPs being conceptually promising and successful in laboratories, their success
has not yet been mirrored in clinical trials [1, 2, 19]. It is hypothesised that this unsuccessful
Bench-to-Bedside translation is partly due to an insufficiently stringent clinical screening
practice of selecting tumours that are suitable for HAP treatments [19]. It is likely that some
of the tumours enrolled in clinical trials have been insufficiently hypoxic to benefit from
treatment plans involving HAPs [1]. To investigate this hypothesis, we here propose a mathe-
matical modelling angle to simulate how spatio-temporal tumour features may impact HAP
efficacy and how scheduling influences the outcome of multimodality HAP-IR treatments in
silico.
Today, mathematical modelling constitutes an indispensable complement to traditional
cancer research [30]. Models provide an opportunity to study biological phenomena in silico
that may not be empirically observable and, moreover, in silico experiments are fast and cheap
to run, easy to reproduce and not directly associated with any ethical concerns. Previous math-
ematical studies have already contributed to the overall understanding of HAPs, quantified
key mechanisms associated to them and illustrated their clinical feasibility. Foehrenbacher
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et al. [31] deployed a Green’s function method, in customised form, and pharmacokinetic/
pharmacodynamic (PK/PD) modelling to quantify anti-cancer bystander effects elicited by the
HAP PR-104 in a simulated, three-dimensional tumour comprising a microvascular network.
Another concurrent article used similar mathematical concepts to compare Class I HAPs to
Class II HAPs and, furthermore, to determine optimal properties for Class II HAPs [23]. Lind-
say et al. [32] developed a stochastic model to study monotherapies and combination therapies
involving HAPs, specifically TH-302, and erlotinib. Amongst other findings, they concluded
that a combination therapy of the two drugs impedes the uprising of drug resistance. Since
HAPs bioreduce to their activated form under hypoxic conditions it follows that AHAP activ-
ity increases with intra-tumoural hypoxia. Accordingly, a previous study by Wojtkowiak et al.
[33] conceptually validated the strategy of amplifying TH-302 activity by deliberately exacer-
bating intra-tumoural hypoxia using exogenous pyruvate. Their study combined mathematical
modelling with metabolic profiling and EPR (electron paramagnetic resonance) imaging, and
HAP dynamics were modelled using reaction-diffusion/convection equations coupled with
fluid-structure interactions. In line with these previous mathematical studies, the aim of this in
silico study is to contribute HAP-related insights gained by mathematical modelling, according
to a Blackboard-to-Bedside [34] approach.
Model
An on-lattice, hybrid, multiscale cellular automaton (CA) is here used to model solid tumours
subjected to HAP and IR monotherapies, as well as HAP-IR combination therapies. Tumour
growth and HAP responses are parameterised by published data from an in vitro study per-
formed by Voissiere et al. [35], in which multicellular tumour spheroids (MCTSs) where
grown and exposed to HAPs. Specifically, we use their data for human chondrosarcoma
HEMC-SS cells exposed to the hypoxia-activated prodrug TH-302. Our mathematical model is
thereafter extended to simulate in vivo drug dynamics in order to investigate scheduling
aspects of HAP-IR combination therapies. The parameters used in this paper can be modified
in order to simulate specific cell-lines and drugs, and model rules can be altered in order to
simulate both in vitro and in vivo cancer cell populations, MCTSs or tumours. Thus, upon the
availability of appropriate data, various tumour scenarios and treatment schedules and doses
can be investigated in silico. Hence the mathematical model presented here constitutes a valu-
able and versatile complement to both in vitro and in vivo experiments. The model used in this
study is an extension of a previous, well-established model presented by Powathil et al. [36].
All parameters used in the model are motivated from experiments and literature, as described
throughout this section, and are summarised Table 1.
Mathematical framework: A cellular automaton (CA)
The CA used in this model allows for spatio-temporal dynamics and intra-tumoural heteroge-
neity including variations in cell-cycle progressions, oxygen levels, drug concentrations and
treatment responses amongst cancer cells [34, 36–38]. The model is multiscale and integrates
both intracellular and extracellular regulations. In vitro experiments have demonstrated that
MCTSs are more HAP-sensitive than are monolayers. This increase in sensitivity has been
attributed to the microenvironment correlated to multilayer cultures [17]. Aspiring to achieve
an in silico model that is as clinically relevant as possible, we here let the CA lattice extend in
three spatial dimensions. The lattice is specifically a square lattice containing 1003 lattice
points, simulating a physical environment of (2mm)3. Thus each voxel in the lattice spans a
volume of (20μm)3 and each lattice point may be occupied by either one cancer cell or extracel-
lular space. These dimensions agree with previous mathematical studies [36], and reported cell
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population densities in the MCTSs that are used to calibrate the model [35]. The time step
used for the temporal progression of the CA is Δt = 10−3 hours, by appropriate non-dimensio-
nalisation of oxygen dynamics [36].
Cell-cycle progression
On an intracellular scale, sub-cellular mechanisms are modelled individually for each cell in
order to allow for variations amongst cancer cells. Cell-cycle progression is one such intracel-
lular process, and it is here governed by an intrinsic cell-cycle clock attributed to each individ-
ual cell. In order to account for cell-cycle asynchronicity amongst cells, each cell i is assigned
an individual, stochastic doubling-time τi which corresponds to the time it takes for a cell to
complete one cell-cycle, and double by producing a daughter cell, under well-oxygenated con-
ditions. Here, τi is picked from a normal distribution [37] with a mean value μ and a standard
Table 1. Model parameters.
Equation Parameter Value
Cellular Automaton
N/A Δx1 = Δx2 = Δx3 (spacing) 20 μm
Δt 0.001 hours
Cell-cycle and proliferation
N/A μ, σ 40 hours, 4 hours












DK=1:5 if cell in ðx; tÞ
DK otherwise
(
DK = 2.5 × 10−5 cm2s−1
cellðx; tÞ ¼




1 if ðx; tÞ outside MCTS
0 otherwise
(
6 h 0.5 mmHg
11 OERm 3
12 Km 3 mmHg
Drugs
7 b (hour)−1
8 [pO2]50 0.2 mmHg
9 and 10 DHAP, DAHAP 2 × DK(x, t), 14� DKðx; tÞ
ηHAP, ηAHAP picked from half-life times:
t1/2,HAP = 0.81 hours,
t1/2,AHAP = 0.70 hours
9 TL!R (for the no removal in vitro case) Infinity
Radiotherapy
13 α(G1), β(G1) 0.351, 0.04
α(S), β(S) 0.1235, 0.04
α(G2), β(G2) 0.793, 0
α(M), β(M) 0.793, 0
α(G0), β(G0) α(G1)/1.5, β(G1)/(1.52)
https://doi.org/10.1371/journal.pcbi.1008041.t001
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deviation σ, which are picked to match cell population growth-rates reported from Voissiere
et al. [35], as demonstrated in Fig 1.
As sensitivity to radiotherapy is cell-cycle dependent [20], it is important to track cell-cycle
phase progression in the model. Thus each cell in the model follows a cell-cycle typical to that
of eukaryotic cells and, in particular, a cell is defined to be in the gap 1 (G1), synthesis (S), gap
2 (G2) or mitosis (M) phase of the cell-cycle. Under well-oxygenated conditions, the fraction
of time spent in each of the four distinct cell-cycle phases areΘG1,ΘS,ΘG2 andΘM for the cell-
cycle phases G1, S, G2, M respectively, where theΘ-fractions sum up to one so that
YG1 þYS þYG2 þYM ¼ 1: ð1Þ
The four theta values are picked from literature in order to match typical cell-cycle phase
lengths of rapidly cycling human cells with a doubling time of roughly 24 hours [40]. Specifi-
cally, we set the G1, S, G2 and M phase to respectively occupy 11/24:ths, 8/24:ths, 4/24:ths and
1/24:th of a cell’s individual doubling time. These values can be amended upon availability of
cell-line specific data. Thus the time spent in each of the four distinct cell-cycle phases, for a
well-oxygenated cell i with a doubling time τi, is here ΘG1 τi,ΘS τi,ΘG2 τi andΘM τi for the
cell-cycle phases G1, S, G2 and M respectively so that
YG1ti þYSti þYG2ti þYMti ¼ ti: ð2Þ
However, low cellular oxygen levels have been shown to delay cell-cycle progression by
inducing arrest in particularly the G1 phase of the cell-cycle [41]. Mathematically, the cell-
cycle can be modelled in various ways. For example, in mechanistic cell-cycle models derived
by Tyson and Novak [42], the cell-cycle is governed by a regulatory molecular network that
can be described by a system of ordinary differential equations. By incorporating hypoxia-
induced factors in the system of equations, the G1 phase can be inherently elongated under
hypoxic conditions [36]. In this study, however, cell-cycle progression is merely modelled
using a phenomenological clock, instead of a more detailed Tyson-Novak type of model. As a
result of this, there is no mechanistic functionality driving G1-arrest under hypoxic conditions
in our model. To remedy this fact, we here introduce an additional function to achieve an
Fig 1. Cell count over time for tumour spheroids. In silico data, based on 10 simulations runs, are represented in
terms of the mean value (black line) and standard deviation (grey ribbon). In vitro data (red error bars) are extracted
from plots produced by Voissiere et al. [35] using a Java program (DataThief III [39]).
https://doi.org/10.1371/journal.pcbi.1008041.g001
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oxygen-dependent elongation of the G1-phase. We name this function the G1 Delay Factor
(G1DF) such that,
G1DFðK^ðx; tÞÞ ¼
2 if 0 mmHg � K^ðx; tÞ < 1 mmHg;
a1 þ
a2
a3 þ K^ðx; tÞ










where K^ðx; tÞ denotes the oxygenation (in units of mmHg) of a cell in point x at time t. The
G1DF, which is illustrated in Fig 2, is an approximation for how much the G1 phase is
expanded in time as a function of oxygen pressure, here measured in units of mmHg. The
G1DF is matched to fit data points extracted from a previous mathematical study by Alarcon
et al. [41], in which a Tyson-Novak cell-cycle model is extended to incorporate the action of
p27, a protein that is upregulated under hypoxia and delays cell-cycle progression. Thus here
the time spent in the G1 phase, τG1, is given by
tG1 ¼ G1DFðK^ðx; tÞÞ �YG1ti; ð4Þ
where G1DFðK^ðx; tÞÞ ¼ 1 for normoxic cells. The lengths of other cell-cycle phases are
approximated as non-oxygen dependent in the model.
Tumour growth
In the model, a tumour is grown from one seeding cancer cell which divides and gives rise to a
heterogeneous MCTS. Each cell that is placed on the lattice commences its first cell-cycle in
the G1 phase and once a viable, i.e. undamaged, cell has completed the mitosis (M) phase of
the cell-cycle, a secondary cell, namely a daughter cell, is produced and placed in the neigh-
bourhood of its mother cell. In the model, cell-division occurs provided that free space is avail-
able on the lattice in the νth order neighbourhood of the mother cell, where the value for ν is
fitted form experimental data [35]. This constraint simulates a scenario in which cell-division
is inhibited by some lack of resources such as space or nutrients. (By setting ν =1, the model
can be adapted to disregard these spatial cell-division constraints [37]). If no free space is avail-
able in the νth order neighbourhood of a mother cell that is ready to divide, no daughter cell is
produced, and instead the mother cell assumes a state in which it progresses through the cell-
cycle very slowly (simulating an in vitro spheroid case, in which inner cancer cells experimen-
tally have shown a reduced proliferation rate [35]), or not at all (simulating an in vivo case in
which cells may enter a quiescent G0 phase [36]). Should neighbourhood space be made avail-
able again, as a result of cells getting removed from the lattice in response to anti-cancer treat-
ments, such slow-cycling or resting cells may reassume an actively cycling state. When cell-
division occurs, a daughter cell is placed on a random lattice point in the neighbourhood of
the mother cell, where up to ν spherical neighbourhoods are regarded and lower order neigh-
bourhood are occupied first. To accomplish spherical-like tumour growth the model stochasti-
cally alternates between deploying Moore and von Neumann neighbourhoods [36] for
daughter cell-placements. In order to agree with the MCTS data [35] used to calibrate the
model, we here pick ν = 3, as illustrated in Fig 3, and thus a daughter cell may be placed up to
three neighbourhoods away from its mother cell. Note that, in the work presented by this
paper, neither necrotic nor apoptotic tumour cells are included in the pre-treatment tumour
growth model, and instead we make the simplifying modelling assumption that the density of
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viable cells is constant (one cancer cell per lattice point) within the simulated MCTSs before
any treatment is given. However, CA are easily adaptable and thus, if appropriate, modelling
rules concerning necrotic and/or apoptotic cells can be included in the mathematical frame-
work. The in vitro experiment produced and reported by Voissiere et al. [35] does detect apo-
ptotic cells in the MCTSs, where these are primarily located towards the center of the
spheroids.
Oxygen distribution and hypoxia
Oxygen is assumed to be readily available outside the tumour and, therefore, lattice points out-
side the tumour are oxygen source points in the model. Viable (i.e. non-damaged) cells are
modelled as oxygen sinks as they consume oxygen in order to function. The distribution of
oxygen across the lattice is modelled by a mechanistic partial differential equation (PDE),
Fig 2. The G1 Delay Factor (G1DF). The G1DF is incorporated in the model to achieve oxygen-dependent G1 arrest. The G1DF (dark line) is
extrapolated from data (red crosses) from a previous mathematical study by Alarcon et al. [41].
https://doi.org/10.1371/journal.pcbi.1008041.g002
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specifically a reaction-diffusion equation such that
@Kðx; tÞ
@t
¼ r � ðDKðx; tÞrKðx; tÞÞ þ rKmðx; tÞ   �KKðx; tÞcellðx; tÞ; ð5Þ
coupled with no-flux boundary conditions. Here, K(x, t) denotes the oxygen level in lattice
point x at time t. DK(x, t) is the diffusion coefficient, which is higher in lattice points occupied
by cells compared to unoccupied lattice points, so that oxygen diffuses slower over cancer cells
than in extracellular space in the model [36]. The binary function cell(x, t) is equal to one if the
lattice point is occupied by a viable cancer cell, and zero otherwise. Similarly, the binary func-
tion m(x, t) is one if the lattice point is outside the tumour and zero otherwise, i.e. m(x, t) = 1 if
the lattice point in (x, t) is neither occupied by a cancer cell, nor enclosed by cancer cells. The
oxygen production rate is denoted by rK and the cellular oxygen consumption rate is ϕK. Thus
the first term in Eq 5 describes oxygen diffusion, the second term describes oxygen sources
and the final term describes cellular oxygen consumption. In the model, the diffusion coeffi-
cient for oxygen is gathered from literature but the production and consumption rates are cali-
brated in silico to match in vitro data from Voissiere et al. [35], specifically to achieve
appropriate oxygen gradients. Note that the no-flux boundary condition causes the total
amount of oxygen on the lattice to increase over time. To express oxygenation levels on the lat-





where maxn K(n, t) denotes the maximal K(x, t)-value (of all n lattice points) at time t [43]. The
scaling-factor, h (with unit mmHg), is incorporated in order to calibrate the model to fit
MCTS data [35], as illustrated in Fig 4. Note that an alternative way of incorporating oxygen
distribution in the model (without having to re-scale the oxygen concentration) is by using an
oxygen source term that is proportional to the difference between some reference oxygen con-
centration Kv (measured inside oxygen sources, e.g. vessels) and the oxygen concentration in
the rest of the domain. Here, a cell is defined to be hypoxic if it has a scaled oxygen value such
that K^ðx; tÞ � 10 mmHg [36], and the K^ðx; tÞ-value influences G1-arrest (Fig 2), HAP-to-
AHAP bioreduction rates (Fig 5) and radio-sensitivity (Fig 6).
Fig 3. Proliferative and slow-cycling or non-proliferative cells. Top: Images from in vitro experiments performed by
Voissiere et al. [35], in which cell nuclei are stained blue and proliferative cells are stained green by the proliferation
marker Ki-67. Bottom: Images from in silico experiments performed in this study, where proliferative (cycling) cells
are coloured green and inner (slow-cycling or non-proliferative) cells are coloured blue.
https://doi.org/10.1371/journal.pcbi.1008041.g003
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Hypoxia-activated prodrugs
Anti-cancer prodrugs constitute relatively harmless compounds in their inactivated form with
the potential to bioreduce, or transform, into cytotoxic species [21]. Specifically for HAPs, this
bioreduction occurs in hypoxic conditions and thus HAPs are able to selectively target hypoxic
tumour regions [21]. The oxygen dependent bioreduction is here modelled by the function
fHAP!AHAPðK^ðx; tÞÞ,
fHAP!AHAPðx; tÞ ¼ b � BRFðK^ðx; tÞÞ; ð7Þ
where b is a time-scaling factor with and BRF is a bioreduction factor as illustrated in Fig 5 and
BRFðK^ðx; tÞÞ ¼
½pO2�50
½pO2�50 þ K^ðx; tÞ
: ð8Þ
Here, [pO2]50 denotes the oxygen value yielding 50% bioreduction (in one hour), chosen to
be 0.2 mmHg, for evofosfamide, as is done in a previous mathematical model by Hong et al.
[44]. As illustrated in Fig 5, the BRF value rapidly decreases for pO2 values (i.e. K^ðx; tÞ values)
between 0 and 10 mmHg. The mechanistic reaction-diffusion equations governing the distri-
bution of HAPs and AHAPs across the lattice are respectively given by [45]
@½HAP�ðx; tÞ
@t
¼ r � ðD½HAP�ðx; tÞr½HAP�ðx; tÞÞ þ r½HAP�ðx; tÞmðx; tÞ




¼ r � ðD½AHAP�ðx; tÞr½AHAP�ðx; tÞÞ
þ fHAP!AHAPðx; tÞ½HAP�ðx; tÞ   Z½AHAP�½AHAP�ðx; tÞ;
ð10Þ
where [HAP](x, t) denotes the concentration of HAPs and [AHAP](x, t) denotes the concen-
tration of AHAPs in point x at time t. D[HAP](x, t) and D[AHAP](x, t) denote the respective diffu-
sion coefficients, r[HAP](x, t) denotes the HAP production rate, η[HAP] and η[AHAP] denote the
corresponding decay rates. AHAPs are harmful agents which are here assumed to inflict dam-
age that is cell-cycle non-specific. Consequently, cells that are in any cell-cycle phase (G1, S,
G2, M), including cells that are in a slow or non-cycling state in the centre of the MCTS, are
Fig 4. Hypoxic and normoxic cells. Top: Images from in vitro experiments performed by Voissiere et al. [35], in
which hypoxic cells are stained green by pimonidazole and normoxic cells are stained blue. Bottom: Images from in
silico experiments performed in this study, where hypoxic cells (pO2� 10 mmHg) are coloured green and normoxic
cells (pO2> 10 mmHg) are coloured blue.
https://doi.org/10.1371/journal.pcbi.1008041.g004
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susceptible to AHAP-inflicted damage in the model. A cell in point x at time t is damaged by
the cytotoxic AHAPs if [AHAP](x, t)�C, whereC is the lethal AHAP concentration thresh-
old. Note that using a threshold value to determine cell fate (death) is a model approximation
and, in reality (in vitro/in vivo), cellular drug responses will depend on several drug (pharma-
cokinetic/pharmacodynamic) factors, as well as specific cell/tumour details. When a cell dies,
it reduces to a membrane-enclosed cell-corpse which is (in vivo) digested by macrophages
[46]. In the model, the time it takes between a cell is declared dying and it is removed from the
lattice is denoted TL!R (L for lethal event, R for removal). Three cases for this time span TL!R
are investigated in this study: (i) the first extreme case in which a dead cell is never removed
from the lattice (simulating an in vitro environment), (ii) the other extreme case in which a cell
is instantaneously removed from the lattice upon receiving lethal damage, and (iii) a mid-way
case in which a cell is removed from the lattice after a time-period corresponding to its dou-
bling time has passed, i.e. TL!R,i = τi. Results using the first case are included in the main
text of this manuscript, and results for cases (ii) and (iii) are provided in the Supporting
Fig 5. The bioreduction factor, BRF. The BRF expresses the fraction of HAP compound that reduces to AHAP compound within one hour as a
function of oxygenation (in mmHg).
https://doi.org/10.1371/journal.pcbi.1008041.g005
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Information (S1 Text) in which we demonstrate that, within the scope of the performed in sil-
ico experiments, this choice of TL!R value does not affect our qualitative findings.
Parameters. In our mathematical model, lattice points outside the tumour are HAP
source points, and from there HAPs are quickly distributed across the lattice. Drug transporta-
tion of HAPs from source points to cells is mediated only by the diffusion term in Eq 9 and
similarly AHAP transportation is mediated only by the diffusion term in Eq 10. Consequently,
the drug diffusion coefficients D[HAP] and D[AHAP] represent all biophysical drug transporta-
tion across the lattice in silico. HAPs must possess certain appropriate attributes in order to
produce desired effects [17]. For example, HAPs should be able to travel relatively long dis-
tances without being metabolised, specifically distances longer than that of which oxygen trav-
els, in order to reach hypoxic tumour regions. As oxygen is consumed by the cells, whilst
HAPs require certain micro-environmental conditions to be met in order to metabolise, HAPs
may reach regions located relatively far away from blood vessels, that oxygen can not reach. It
Fig 6. The probability that a cell, in the mathematical model, exposed to a radiotherapy dose of 2 Gy survives. The survival probability S(x, t) is
function of a cell’s current cell-cycle phase and oxygenation value, as well as the applied radiotherapy dose. Cells are the most likely to survive
radiotherapy when hypoxic.
https://doi.org/10.1371/journal.pcbi.1008041.g006
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has, indeed, been demonstrated in vivo that TH-302 has the ability to reach hypoxic regions,
where it is activated [47]. Conversely, AHAPs should ideally travel relatively short distances in
order to localise AHAP activity to tumour regions only, and thus to minimise unwanted extra-
tumoural toxicity. The diffusion length of oxygen is reported in literature to be approximately
100 μm [36] however, to our knowledge, no diffusion length of neither TH-302 nor Br-IPM
has been explicitly reported. However, the diffusion length of the HAP/AHAP pair AQ4N/
AQ4 has been shown to be reach roughly 1.5 times that of oxygen (or 150μm) in xenografts
[48]. With this motivation, we here approximate the diffusion coefficient of TH-302 to be




, where L is the diffusion length
scale,F is the compound uptake and the diffusion coefficient of a certain compound, D, is pro-
portional to L2, neglecting details of compound uptake [36]. Thus here we make the simplified




� DKðx; tÞ � 1:5 � DKðx; tÞ. Similar to previous proce-
dure, the diffusion length of AHAPs is approximated to be half that of oxygen from which it
follows that D[AHAP](x, t) = (1/4) � DK(x, t). These parameter estimations suffice to conceptu-
ally, and qualitatively, describe the nature of HAPs and AHAPs, but can be amended upon the
availability of new data. By adjusting the diffusion coefficient D[AHAP], the influence of
bystander effects are allowed to range from negligible to highly influential in our mathematical
framework. The half-life times of TH-302 and Br-IPM have been reported to be 0.81h and
0.70h respectively in a clinical trial [11], these values are used to determine the decay rates
η[HAP] and η[AHAP]. This half-life time of TH-302 is in accordance with preclinical predictions
obtained from allometric scaling [26]. Note that the drug decay coefficients, η[HAP] and
η[AHAP] in Eqs 9 and 10 respectively, simulate all drug clearance from the system, i.e. both met-
abolic clearance and excretion.
Radiotherapy
Cellular responses to radiotherapy are dependent on oxygenation status [4], cell-cycle phase
[49, 50], and cell-line characteristics. Cellular radiotherapy responses are here modelled using
an appropriate CA adaptation of the widely accepted Linear-Quadratic (LQ) model. In the tra-
ditional LQ model, the survival fraction of a cell population is given by S(d) = e−nd(α+βd), where
d is the radiation dosage, n is the number of administered radiation fractions and α and β are
cell-line specific sensitivity parameters [51]. In order to include cell-cycle sensitivity, α and β
are here cell-cycle dependent and the oxygen modification factor (OMF) is incorporated to







OERm � K^ðx; tÞ þ Km
K^ðx; tÞ þ Km
: ð12Þ
Here, OERm = 3 is the maximum value under well-oxygenated conditions and Km = 3
mmHg is the pO2 value achieving half of the maximum ratio [43]. The OER and OMF func-
tions are illustrated in Fig 7.
The survival probability of a cell in point x at time t is here given by
Sðx; tÞ ¼ e  dð½OMF�aðx;tÞþd½OMF�2bðx;tÞÞ; ð13Þ
where the cell-cycle phase specific α and β values are gathered from a previous study by Kempf
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et al. [53], and are listed in Table 1. Cellular responses to a 2 Gy IR dose for a generic cancer
cell-line, as a function of oxygenation and cell-cycle phase details, are illustrated in Fig 6.
Parameters
In this study we attempt to replicate the nature of generic eukaryotic cell-lines, the HAP evo-
fosfamide (TH-302) and its corresponding AHAP, Br-IPM. The parameters, which are listed
in Table 1, are chosen accordingly but can be adapted to represent other specific cell-lines or
drugs upon data becoming readily available.
Implementation and in silico framework
The mathematical model is implemented in an in-house computational framework written in
C++ deploying high-performance computing techniques. The PDEs describing oxygen and
Fig 7. The oxygen enhancement ratio (OER) and the oxygen modification factor (OMF). The OER and the OMF are incorporated in the
mathematical model to quantify the influence of oxygen on radiotherapy responses. Cells are the least radiosensitive for low pO2 values. The OER and
OMF curves have steep gradients between the oxygen values 0 and 10 mmHg, after which they respectively asymptote to the values 3 and 1 for higher
oxygen values.
https://doi.org/10.1371/journal.pcbi.1008041.g007
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drug distribution across the lattice are solved using explicit finite difference methods with no-
flux boundary conditions. Maps of cancer cells and the microenvironment are visualised in
ParaView [54]. Using this computational framework, various experimental in vitro and in vivo
scenarios are formulated and simulated in silico. In order to grow an in silico MCTS, one seed-
ing cancer cell is placed on the lattice, this cell divides and gives rise to a MCTS that is hetero-
geneous in nature, as in-built model stochasticity creates cell-cycle asyncronosity amongst
tumour cells [55], and oxygen levels vary across the MCTS. Such virtual spheroids are thereaf-
ter subjected to various treatments comprising HAPs and/or IR. Treatments commence when
the MCTSs consist of, in the order of, 100,000 cancer cells or ‘agents’ in our agent-based
model. Due to the high number of agents, and the fact that the intrinsic model stochasticity
only involves a few events during the simulated treatment time (specifically 0-3 cell divisions
and potentially one response to radiotherapy) the quantitative results do not differ much
between in silico runs. Performing the same in silico experiment 10 times yields a standard
deviation that can be regarded as negligible (as the standard deviations obtained in this study
are less than 0.5% of the mean values). From this we argue that basing our results on mean val-
ues from 10 simulation runs per experiment is enough to mitigate intrinsic model stochasticity
to a sufficient level for this qualitative study.
Results and discussion
In the following sections, we compare treatment responses in two different in silico tumour
spheroids, specifically a ‘Large’ and more hypoxic MCTS and a ‘Small’, less hypoxic MCTS.
The ‘Small’ MCTS corresponds to the 20 day-old MCTS in Figs 3 and 4, that is calibrated by in
vitro data from Voissiere et al. [35]. The ‘Large’ MCTS is extrapolated by letting the ‘Small’
MCTS grow for yet another 10 days in silico, until it reaches an age of 30 days. The ‘Small’ and
‘Large’ MCTSs are illustrated in Fig 8.
The simulated IR dose is chosen to be 2 Gy and, to allow for intuitive comparisons between
the two different monotherapies, the HAP dose (DoseHAP) is here qualitatively chosen, and cal-
ibrated to yield the a similar in silico response as the 2 Gy IR dose (in terms of cell survival) in
the ‘Large’ MCTS. Quantitative drug doses can be specified and implemented upon the avail-
ability of data.
HAP and IR monotherapies attack tumours in different ways
In this initial in silico experiment, a MCTS is subjected to a monotherapy of either one dose of
HAPs or one dose of IR. Our in silico results demonstrate that HAP and IR monotherapies
attack the MCTS in different ways. This can be understood by regarding the treatment
responses in Figs 9 and 10. Fig 9 shows cell-cycle phase specific survival data, in terms of cell
count over time, when the ‘Small’ or ‘Large’ MCTS is subjected to a HAP or IR monotherapy.
Similarly, Fig 10 shows the composition of cells, in terms of their cell-cycle phase, in response
to a HAP or IR monotherapy dose. Our results demonstrate that for the ‘Small’, well-oxygen-
ated MCTS, HAPs have negligible effect on the cell count (see Fig 9) and, by extension, on the
cell-cycle phase composition (see Fig 10). This shows that, by design, HAP treatments have lit-
tle effect on tumours that are not hypoxic enough to cause significant HAP-to-AHAP biore-
duction. For the ‘Large’ MCTS, however, HAPs successfully eliminate cells, particularly the
inner cells of the MCTS, labeled ‘slow/non-proliferative’ (see Fig 9). This causes a change in
the cell-cycle phase composition in favour of the proliferative cells in the outer shell of the
MCTS (see Fig 10). Our results further show that, for both the ‘Small’ and the ‘Large’ MCTSs,
IR eliminates cells of all cell-cycle states (see Fig 9), but alters the cell-cycle phase composition
in favour of the inner, hypoxic cells as these are less sensitive to radiotherapy (see Fig 10).
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Fig 8. The ‘Small’ (20 day old) MCTS and the ‘Large’ (30 day old) MCTS. These two MCTSs are used to allow for comparisons in
treatment responses between tumours with different oxygenation levels. Top: Simulation snapshots of the MCTSs at the time point T0 when
treatments commence (A1: Small MCTS, B1: Large MCTS). Hypoxic cells (pO2� 10 mmHg) are green whilst normoxic cells are blue.
Middle: Oxygen histograms at time T0, in which hypoxic cell counts are shown in green and normoxic cell counts are shown in blue (A2:
Small MCTS, B2: Large MCTS). Bottom: Cell-cycle phase histograms at time T0 (A3: Small MCTS, B3: Large MCTS). The slow/non-
proliferative, inner cancer cells are labeled S/N-P.
https://doi.org/10.1371/journal.pcbi.1008041.g008
PLOS COMPUTATIONAL BIOLOGY Combining hypoxia-activated prodrugs and radiotherapy in silico
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008041 August 3, 2020 16 / 27
These opposing effects on the cell-cycle phase composition achieved by HAPs and IR in the
‘Large’ MCTS indicate that, for tumours that are hypoxic enough for HAPs to have an effect,
HAP-IR combination treatments have the potential of producing multifaceted attacks on
tumours.
Since radiation responses are enhanced by the presence of molecular oxygen, we investi-
gated which monotherapy (i.e. HAP or IR) best eliminates hypoxic cells and re-oxygenates
MCTSs after one single treatment dose. To demonstrate the overall change of oxygenation lev-
els in the MCTSs, as a result of the monotherapies, Fig 11 provides histograms for cellular oxy-
genation levels at time T0 (the time of therapy administration) and at time T0 + 4 hours. From
this figure we can see that for the ‘Small’ MCTS, HAPs do not alter the overall intra-tumoural
oxygenation but IR does, since HAPs are not effective but IR is. For the ‘Large’ MCTS, on the
other hand, both HAPs and IR alter the overall intra-tumoural oxygenation but only HAPs
manage to eliminate the most hypoxic cells, and thus shift the oxygen histogram away from
the most severe levels of hypoxia. This indicates that administering HAPs as a neoadjuvant
therapy prior to radiotherapy may enhance the effect of radiotherapy in tumours that are suffi-
ciently hypoxic for HAPs to be effective.
Fig 9. Monotherapy results: Cell count. Treatment responses for HAP (left) and IR (right) monotherapies for the ‘Small’ (top) and ‘Large’
(bottom) MCTS. The monotherapy is given at T0 = 0 hours. Graphs demonstrate cell-cycle specific cell count (i.e. number of viable,
undamaged cells) over time. The slow/non-proliferative, inner cancer cells are labeled S/N-P. Solid lines show mean values, and the height of
‘+’ markers show standard deviations for 10 in silico runs.
https://doi.org/10.1371/journal.pcbi.1008041.g009
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HAP-IR treatment scheduling impacts HAP efficacy in sufficiently hypoxic
tumours
In order to study the optimal treatment scheduling of HAP-IR combination therapies, simu-
lated MCTSs are here given one dose of HAPs and one dose of IR, using different schedules.
Fig 12 shows the cell count over time when one dose of HAPs and one dose of IR are adminis-
tered with various schedules. Specifically, either HAPs are given at 0 hours (followed by IR at
0, 12, 24 or 48 hours) or IR is given at 0 hours (followed by HAPs at 12, 24 or 48 hours). The
results in Fig 12 demonstrate that for the ‘Small’ MCTS, scheduling does not impact the overall
treatment outcome, as HAPs with the chosen [pO2]50 value are not effective. For the ‘Large’
MCTS however, it is here more effective to give HAPs before IR, than to give IR before HAPs.
This indicates that, in tumours that are hypoxic enough for HAPs (with certain [pO2]50 values)
to be effective, the HAP-IR treatment scheduling impacts the efficacy of the combination treat-
ment. Note that, as is demonstrated in the Supporting Information (S1 Text), the [pO2]50 value
will affect the impact and importance of treatment scheduling.
Fig 10. Monotherapy results: Cell cycle phase composition. Treatment responses for HAP (left) and IR (right) monotherapies for the
‘Small’ (top) and ‘Large’ (bottom) MCTS. The monotherapy is given at T0 = 0 hours. Graphs demonstrate cell-cycle specific composition (of
viable, undamaged cells) over time. The slow/non-proliferative, inner cancer cells are labeled S/N-P. Solid lines show mean values for 10 in
silico runs (standard deviations are negligible hence not shown).
https://doi.org/10.1371/journal.pcbi.1008041.g010
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HAPs enhance radiotherapy effects in sufficiently hypoxic tumours
To investigate if and when HAPs enhance the effect of radiotherapy, simulated MCTSs are
subjected to either IR monotherapies or HAP-IR combination therapies. In the combination
therapy case, HAPs are administered at time T0 and IR is administered at time T0 + 48 hours.
In the monotherapy case, radiotherapy is administered at time T0 + 48 hours. For a thorough
investigation, the oxygen-levels of the ‘Large’ and ‘Small’ tumours are further scaled by multi-
plication with a factor 1, 1/2 or 1/4 so that we have 6 different tumours on which to test if
neoadjuvant HAPs enhances radiotherapy efficacy. Fig 13 shows IR treatment responses in
form of survival data (both in terms of number of surviving cells and fraction of surviving
cells). From these plots we see that for very hypoxic MCTSs, the administration of neoadjuvant
HAPs does increase the effect of radiotherapy. However, for well-oxygenated MCTS, neoadju-
vant HAPs do not increase the effect of radiotherapy.
The intra-tumoural oxygen landscape impacts HAP efficacy
Above, we have demonstrated various ways that the intra-tumoral oxygenation level impacts
HAP and IR monotherapies and combination therapies. Further, in order to investigate if the
Fig 11. Monotherapy results: Oxygen histograms. Treatment responses for HAP (left) and IR (right) monotherapies for the ‘Small’ (top) and
‘Large’ (bottom) MCTS. Histograms over cellular oxygenation levels at time T0 (monotherapy administration time) and 4 hours later are shown.
Results are based on mean values from 10 in silico runs.
https://doi.org/10.1371/journal.pcbi.1008041.g011
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spatio-temporal intra-tumoral oxygen landscape impacts HAP efficacy, two MCTSs with dif-
ferent oxygen landscapes are here compared. Omitting details of oxygen dynamics and vessel
structure, hypoxic regions are here manually assigned in the MCTSs so that every cancer cell is
set to be either severely hypoxic (pO2 = 1 mmHg) or very well-oxygenated (pO2 = 100
mmHg). Both MCTSs, named MCTS A and MCTS B, are assigned the same number of
severely hypoxic and well-oxygenated cancer cells at the time-point when treatment com-
mences. In MCTS A, the hypoxic region is made up of one concentric sphere in the core of the
MCTS, whilst in MCTS B, the hypoxic regions consist of multiple spheres, evenly spread out
across the MCTS. MCTS A and MCTS B are illustrated in Fig 14. The severely hypoxic cancer
cells are here called activator cells, as the prodrug bioreduction (or activation) is maximal in
severly hypoxic environments. The well-oxygenated cells are here referred to as bystander cells,
as the bioreduction is minimal in well-oxygenated environments. Thus any lethal AHAP con-
centration occurring in a bystander cell is a result of HAP-to-AHAP bioreduction occurring
outside the bystander cells.
From Fig 15 it is clear that the bystander effects are higher in MCTS B than in MCTS A,
although all activator cells are eliminated in both MCTSs. When the activator cells are spread
out across the spheroid, as in MCTS B, there are more interfaces in which bystander cells
Fig 12. Combination treatment results: Scheduling. Treatment responses (in terms of cell count) for HAP-IR combination therapies in the
‘Small’ MCTS (left) and the ‘Large’ MCTS (right). One dose of HAPs and one dose of IR are administered at various schedules. Solid and
dashed lines show mean values, and the height of the ‘+’ markers show standard deviations for 10 in silico runs.
https://doi.org/10.1371/journal.pcbi.1008041.g012
PLOS COMPUTATIONAL BIOLOGY Combining hypoxia-activated prodrugs and radiotherapy in silico
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008041 August 3, 2020 20 / 27
experience significant bystander effects. Although the oxygen landscape in MCTS B is highly
synthetic, this in silico experiment shows that the intra-tumoural oxygen landscape does
impact the efficacy of HAPs. In the Supporting Information (S1 Text), more MCTSs with dis-
tinct oxygen landscapes, subjected to HAP monotherapies are explored.
Conclusion
Previous in vitro and in vivo studies have validated the successfulness of HAPs in laboratory
settings, however, this preclinical success has not yet been reflected in clinical trials. In an
attempt to elucidate the unsatisfactory results from clinical HAP trials, we in this study investi-
gate how oxygen-related tumour features and treatment scheduling impact the efficacy of
HAP monotherapies and HAP-IR combination therapies in silico. To this end, we have devel-
oped a mathematical model capturing the spatio-temporal dynamics of tumours subjected to
multimodality treatments comprising HAPs and IR. A set of key results (1 to 4) relating to
(Class II) HAP efficacy in silico have here been demonstrated.
1. HAPs and IR attack tumours in different, complementary, ways. Whilst IR provides a
highly effective way to kill cancer cells, tumour regions containing hypoxic and resting cells
are significantly more resistant to IR than are tumour regions with well-oxygenated and
Fig 13. Combination treatment results: HAPs as IR-treatment intensifiers. Treatment responses of radiotherapy in various MCTSs
when either (1) an IR monotherapy dose is administered at T0+ 48 hours or (2) IR is given at T0+48 hours following a prior HAP dose at
time T0. Note that only explicit IR responses (not HAP responses) are shown. The oxygen-levels of the ‘Small’ (left) and ‘Large’ (right)
tumours are scaled by a factor of 1 (least hypoxic), 1/2 or 1/4 (most hypoxic). The value calibrated from in vitro experiments [35]
correspond to a scaling with factor 1. Orange + blue bars show number of viable cells (instantaneously) before IR administration, blue bars
show the number of viable cells (instantaneously) post IR. Red bars show how many cells (as a fraction) survived the IR attack.
https://doi.org/10.1371/journal.pcbi.1008041.g013
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actively cycling cells. HAPs, however, are alkylating agents which bioreduce in (primarily)
hypoxic areas, hence HAPs mainly inflict damage in hypoxic tumour regions. Conse-
quently, HAP-IR combination treatments have the potential to produce multifaceted
attacks on tumours with heterogeneous oxygen landscapes.
2. HAP-IR treatment scheduling may impact treatment efficacy. The impact of scheduling is
apparent in tumours that contain regions that are hypoxic enough for IR to be ineffective
(when the HAP bioreduction is, in most part, restricted to occur in those regions).
3. HAPs may function as IR treatment intensifiers in tumours that contain hypoxic regions in
which IR is ineffective.
4. Not only the overall intra-tumoural oxygenation levels, but also the intra-tumoural oxygen
landscape, impacts the efficacy of HAP monotherapies.
In this study, we qualitatively investigated various aspects of HAP-IR treatment schedules
using a multiscale mathematical framework. Upon the availability of in vitro and in vivo data,
this mathematical framework can be calibrated in order to serve as an in silico testbed for pre-
dicting HAP-IR treatment scenarios. As a result of interdisciplinary collaborations, the mathe-
matical framework used in this study has previously been validated in vitro and in vivo for
applications other than HAP-IR combination treatments [37, 56]. The multiscale nature of the
framework enables integration of data from various scales, be it from the subcellular scale, the
cellular scale or the tissue scale. For example, the multi cellular tumour spheroid data previ-
ously produced by Voissiere et al. [35] provided our framework with calibration data for
tumour growth and spatio-temporal oxygen dynamics. Using existing experimental data to
Fig 14. Multicellular tumour spheroids (MCTSs) A and B prior to treatment commencing. The MCTSs are visualised in both opaque and
transparent formats. Hypoxic activator cells are shown in green and normoxic bystander cells are shown in blue. Activator and bystander cells are
manually set so that MCTSs A and B contain the same number of activator and bystander cells before treatment commences.
https://doi.org/10.1371/journal.pcbi.1008041.g014
PLOS COMPUTATIONAL BIOLOGY Combining hypoxia-activated prodrugs and radiotherapy in silico
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008041 August 3, 2020 22 / 27
create data-driven mathematical models is a resourceful step involved in the advancement of
mathematical oncology [57].
In a recent publication, Spiegelberg et al. [19], claim that the (lack of) clinical progress with
HAP-treatments can, in great part, be attributed to the omission of hypoxia-based patient
selection. Our in silico study demonstrates that whilst (class II) HAPs are effective treatment
intensifiers for sufficiently hypoxic tumours, they have negligible effect on more well-oxygen-
ated tumours. In simple terms: some tumours are suitable to be paired with treatment plans
involving HAPs whilst others are not. In line with Spiegelberg et al.’s claims [19], our in silico
results indicate that a personalised medicine approach is preferable if treatments involving
HAPs (that are similar to TH-302) are to achieve their maximum potential in clinical settings.
Note here that intra-tumoural oxygenation status can be assessed in multiple ways. For exam-
ple, by inserting oxygen electrodes into tumours, pO2 values can directly be measured, how-
ever this measuring technique is invasive and does not distinguish between hypoxic and
necrotic tumour regions [19]. Less invasive imaging techniques, such as positron emission
(PET-scans) and oxygen-enhanced magnetic resonance (MRIs), can also be used to evaluate
oxygen levels in tumours [2, 19]. Moreover, there now exist several hypoxia gene expression
signatures that may be used to characterise hypoxia-related tumour features [19]. Without fur-
ther going into the advantages and disadvantages of various hypoxia assessment methods, the
above discussion illustrates that, in line with a personalised medicine approach, it is indeed
feasible to invoke stricter selection regimes when deciding whether or not to pair tumours
with HAP treatments in clinical trials [19].
Fig 15. Treatment responses in multi-cellular tumour spheroid (MCTS) A and MCTS B when HAPs are administered at T0 = 0 hours. The number
of viable (undamaged) cells are plotted over time for MCTS A and MCTS B. Cell counts for activator cells (pO2 = 1 mmHg) are shown in dashed lines and
bystander cell counts (pO2 = 100 mmHg) are shown in solid lines. Results demonstrate mean values for 10 in silico runs.
https://doi.org/10.1371/journal.pcbi.1008041.g015
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